This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Guidance in Line

Updated from 8:35 a.m.

Abbott Laboratories (ABT - Get Report) swung to a fourth-quarter loss on acquisition-related costs, but adjusted profits and sales were higher than expected.

The company also guided in line for 2007. Shares were flat in midmorning trading.

The health care giant lost 31 cents a share in the quarter, including 82 cents in charges related to its purchase of Kos Pharmaceuticals. In the year-ago quarter, the company earned 63 cents a share.

Excluding items, Abbott would have earned 75 cents a share, at the high end of its guidance of 73 cents to 75 cents. Analysts were expecting the company to earn 74 cents a share.

Sales were $6.22 billion, up 2.8%, exceeding the consensus target of $6.18 billion. Including an amendment of a distribution agreement with Boehringer Ingelheim, worldwide sales increased 14.5%, the company said in a press release Wednesday.

U.S. pharmaceutical sales sank 18.2% but gained 9.9% including the impact of the Boehringer Ingelheim agreement. Sales of Abbott's drug Humira were up 31% to $370 million in the quarter, with 85% of its sales for the treatment of rheumatoid arthritis.

"We are well-positioned to gain share in this large and fast growing biologic market for years to come," said Rick Gonzalez, Abbott's chief operating officer, in the company's conference call Wednesday morning. Last year, the drug received Food and Drug Administration additional approvals to treat psoriatic arthritis and ankylosing spondylitis.

Revenue from the antibiotic Biaxin declined 40% to $56 million and Abbott expects sales to be "very modest" going forward. Medical product sales rose 22.7%. This segment includes drug-eluting stent sales of between $35 million and $40 million, the company says.

"We completed several major transformational changes that significantly strengthened the mix of our broad-based portfolio as well as the diversity of our strong cash flows," said Miles White, Abbott's chairman and CEO. "The strategic actions we've taken over the last seven to eight years have positioned Abbott for higher growth and consistent double-digit earnings performance."

Excluding certain items, the company expects to earn $2.77 to $2.83 in 2007, with earnings of 51 to 53 cents in the first quarter. This includes the sale of Abbott's core laboratory and point of care diagnostic businesses. That deal, with General Electric (GE), is expected to close in the first half of 2007.

Sales are expected to grow 13% to 15% for the year, including a return to double digit growth within its diabetes care segment, the company says. Analysts were looking for a profit of $2.79.

Shares dipped 6 cents to $53.33 Wednesday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.10 -1.17%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs